Jardiance and Pregabalin Interaction: What Patients and Prescribers Need to Know

How Empagliflozin and Pregabalin Are Each Eliminated

Knowing each drug's elimination pathway is the first step in assessing whether a pharmacokinetic interaction is possible between them.

Empagliflozin Metabolism and Excretion

Empagliflozin undergoes glucuronidation primarily via UGT1A3, UGT1A8, UGT1A9, and UGT2B7, and is not a meaningful substrate or inhibitor of CYP3A4, CYP2C8, or P-glycoprotein at therapeutic doses [1]. The FDA-approved prescribing information confirms that approximately 54% of an oral dose is recovered in feces and about 41% in urine [1]. Because cytochrome P450 enzymes play a negligible role, drugs that inhibit or induce CYP pathways do not significantly alter empagliflozin plasma levels.

Renal function does, however, directly govern efficacy. The FDA label for empagliflozin states that the drug is not recommended for glycemic control when eGFR falls below 30 mL/min/1.73 m², though it retains a cardiovascular and renal indication down to eGFR >20 mL/min/1.73 m² based on data from the EMPA-REG OUTCOME trial (N=7,020) [2].

Pregabalin Metabolism and Excretion

Pregabalin is structurally related to gamma-aminobutyric acid (GABA) but does not act on GABA receptors directly. Instead, it binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release [3]. More than 98% of an absorbed dose is excreted unchanged in urine, and pregabalin is not bound to plasma proteins and is not metabolized by CYP enzymes [3]. This clean renal clearance profile means pregabalin's elimination will mirror GFR decline almost linearly.

The FDA label for pregabalin (Lyrica) specifies dose reduction for creatinine clearance below 60 mL/min, with further reductions required stepwise down to CrCl <15 mL/min [4].

Why No CYP or Transporter Interaction Exists

Because neither empagliflozin nor pregabalin relies on CYP3A4, CYP2C9, or P-glycoprotein as a primary clearance mechanism, co-administration does not produce the kind of exposure-altering interaction seen with, for example, clarithromycin and a CYP3A4 substrate. Standard pharmacokinetic DDI screening databases classify this combination as having no interaction at the enzyme or transporter level.

The Real Risk: Pharmacodynamic Overlap

The absence of a pharmacokinetic interaction does not mean the combination is without risk. Three overlapping pharmacodynamic effects deserve attention.

Volume Depletion and Orthostatic Hypotension

Empagliflozin's mechanism of action is osmotic diuresis. By blocking the sodium-glucose cotransporter 2 in the proximal tubule, the drug causes glucosuria and associated natriuresis, reducing plasma volume by an estimated 7% within the first two weeks of therapy in some patients [5]. The EMPA-REG OUTCOME trial (N=7,020) reported that volume depletion events occurred in 2.4% of the empagliflozin group versus 1.6% of the placebo group [2].

Pregabalin causes dose-dependent peripheral edema and dizziness in a meaningful fraction of users. In the pooled data reviewed for the Lyrica FDA label, dizziness was reported in 29% of patients receiving pregabalin 300 mg/day for diabetic peripheral neuropathy versus 9% in the placebo arm [4]. When pregabalin's vasodilatory peripheral edema combines with SGLT2-inhibitor-driven intravascular volume contraction, the net hemodynamic result can tip susceptible patients into symptomatic orthostatic hypotension.

CNS Depression and Fall Risk

Pregabalin carries a Schedule V controlled substance classification due to its CNS depressant properties, including somnolence, cognitive impairment, and balance disturbance [4]. Somnolence was reported in 21% of pregabalin-treated patients at 600 mg/day in registration trials for diabetic neuropathy versus 5% on placebo [4]. Dizziness from SGLT2-inhibitor-related volume depletion combined with pregabalin-related CNS sedation creates a compound fall risk that is particularly relevant for patients over age 65.

A 2019 cohort study published in BMJ (N=90,112) found that SGLT2 inhibitors were associated with a lower fracture risk than other antidiabetic agents in general, but the authors noted that acute volume depletion events in the first 30 days of therapy independently predicted fall-related injury [6].

Shared Renal Dependency

Because both drugs depend on renal clearance, any acute kidney injury or progressive CKD will simultaneously raise plasma concentrations of both agents. A patient whose eGFR drops from 55 to 32 mL/min after a dehydrating illness may experience pregabalin accumulation (with worsening sedation and ataxia) and reduced empagliflozin efficacy at the same time. The 2023 KDIGO Diabetes Management in CKD guideline recommends reassessing all renally cleared medications whenever eGFR declines by more than 25% from baseline [7].

Severity Classification Across DDI Databases

Most major DDI databases, including Lexicomp, Micromedex, and the FDA's drug interaction database, list the empagliflozin-pregabalin combination as a minor or no-interaction pair when only pharmacokinetic criteria are applied. The pharmacodynamic component typically shifts the clinical severity to "moderate" in risk-stratified patients. The table below summarizes how severity maps to patient phenotype:

| Patient Profile | PK Interaction | PD Risk Level | Recommended Action | |---|---|---|---| | Age <65, normal eGFR, no diuretics | None | Low | Standard counseling | | Age >65 or eGFR 30-60 mL/min | None | Moderate | BP monitoring, fall counseling | | Concurrent loop diuretic | None | Moderate-High | Volume assessment at initiation | | eGFR <30 mL/min | None | High | Pregabalin dose reduce; reassess empagliflozin indication | | Prior syncopal episode or fall | None | High | Consider alternatives; specialist input |

Monitoring Parameters in Clinical Practice

Appropriate monitoring converts a theoretical pharmacodynamic risk into a manageable clinical plan.

Blood Pressure and Volume Status

Orthostatic blood pressure should be checked at the time of empagliflozin initiation (or pregabalin dose uptitration, whichever comes later) and again at the two-to-four-week follow-up visit. A drop in systolic BP of 20 mmHg or more on standing, or a symptomatic event such as lightheadedness on rising, warrants reassessment of the SGLT2 inhibitor dose or the pregabalin dose or both.

Patients should be asked about fluid intake, particularly in summer months or during febrile illness, as SGLT2 inhibitors carry a label warning about dehydration [1].

Renal Function

The 2022 American Diabetes Association Standards of Care recommend monitoring eGFR and serum creatinine at least annually in patients on SGLT2 inhibitors, with more frequent checks for those whose baseline eGFR is between 30 and 60 mL/min/1.73 m² [8]. Because pregabalin dose reduction thresholds are tied to creatinine clearance, the same monitoring schedule serves both drugs efficiently.

Sedation and Cognitive Function

Ask specifically about daytime somnolence, unsteadiness, or near-falls at each visit if pregabalin is being used concurrently. The Mini-Cog or a simple timed up-and-go test takes under three minutes and provides a documented baseline for older patients.

Dose Adjustment Guidance

Empagliflozin Dose Adjustments

The approved doses of empagliflozin are 10 mg and 25 mg once daily. No dose reduction based on body weight or age is required, but the drug should not be initiated when eGFR is below 30 mL/min/1.73 m² for the diabetes indication [1]. For heart failure and CKD indications, the FDA label permits use down to eGFR >20 mL/min/1.73 m² based on outcomes from EMPEROR-Reduced (N=3,730) and EMPA-KIDNEY (N=6,609) [9][10].

Pregabalin Dose Adjustments

The FDA label for pregabalin specifies the following renal dose adjustments [4]:

• CrCl >60 mL/min: standard dosing (up to 600 mg/day for neuropathic pain)
• CrCl 30-60 mL/min: reduce total daily dose by 50%
• CrCl 15-30 mL/min: reduce total daily dose by 75%
• CrCl <15 mL/min: maximum 75 mg/day

Patients on both drugs whose CrCl crosses a pregabalin dose-reduction threshold should have pregabalin adjusted first, since accumulated pregabalin more directly produces CNS adverse events (ataxia, confusion, respiratory depression at extreme levels) than inadequately dosed empagliflozin.

Patient Counseling Points

Effective counseling does not require patients to understand glucuronidation. It requires plain-language framing of specific risks.

What to Tell Patients

Patients taking both drugs should understand three things. First, Jardiance causes the kidneys to spill sugar and water into the urine, which slightly reduces fluid volume in the body. Second, pregabalin can cause dizziness and drowsiness, especially at higher doses or during dose increases. Third, when both effects occur together, the risk of feeling lightheaded when standing up is higher than with either drug alone.

Concrete instructions: drink at least 6 to 8 cups of water daily unless a physician has restricted fluids. Rise slowly from a sitting or lying position. Report any episode of fainting, near-fainting, or an unexpected fall to the prescriber promptly.

Driving and Operating Machinery

Pregabalin's FDA label includes a warning about impaired driving ability [4]. Patients should be counseled not to drive until they know how pregabalin affects them personally, and to be extra cautious if SGLT2-inhibitor-related fluid shifts are causing additional lightheadedness.

Sick-Day Rules

Both drugs carry specific sick-day considerations. Empagliflozin should be held during acute illness, surgery, or prolonged fasting due to the risk of euglycemic diabetic ketoacidosis (DKA), a condition in which DKA occurs despite near-normal glucose levels [1]. The FDA issued a safety communication on this risk in 2015 and again updated SGLT2 inhibitor labeling in 2020 [1]. During the same illness episode, reduced fluid intake will also raise pregabalin concentrations if kidney clearance falls. Patients should be given a written sick-day protocol naming both medications.

Special Populations

Older Adults (Age 65 and Above)

The American Geriatrics Society Beers Criteria (2023 update) flags pregabalin as a drug to use with caution in older adults because of its CNS effects, with particular attention to fall and fracture risk [11]. SGLT2 inhibitors are not listed in the Beers Criteria as inherently inappropriate for older adults, but volume depletion risk is explicitly noted in the prescribing information as more likely in patients aged 65 and older [1]. Combining the two drugs in this population calls for a lower threshold to check orthostatic vitals.

Patients with Diabetic Peripheral Neuropathy

This population is perhaps the most likely to receive both drugs simultaneously. Empagliflozin is used for glycemic control or cardiorenal protection, while pregabalin is a first-line agent for painful diabetic neuropathy per the 2022 ADA Standards of Care [8]. The neuropathy itself may impair autonomic reflexes, reducing the cardiovascular compensatory response to orthostatic stress. A patient with significant autonomic neuropathy has a narrower safety margin for any additional hemodynamic perturbation.

Patients with Heart Failure

The EMPEROR-Reduced trial showed that empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (HR 0.75, 95% CI 0.65-0.86, P<0.001) in patients with HFrEF [9]. Pregabalin is sometimes prescribed in this population for neuropathic pain or anxiety-related symptoms. Peripheral edema, already common in heart failure, may be worsened by pregabalin's peripheral edema adverse effect in up to 16% of patients at standard doses [4]. This warrants explicit discussion about weight monitoring and edema assessment at each visit.

Summary of the Evidence Base

The evidence supporting this interaction analysis draws from the empagliflozin FDA prescribing information [1], the EMPA-REG OUTCOME trial [2], the pregabalin FDA prescribing information [4], the EMPEROR-Reduced trial [9], the EMPA-KIDNEY trial [10], the 2023 KDIGO Diabetes-CKD guideline [7], and the 2022 ADA Standards of Care [8]. No prospective pharmacokinetic study has specifically co-administered empagliflozin and pregabalin in human subjects, which reflects the low pharmacokinetic interaction potential rather than a research gap.

The 2022 ADA Standards of Care note that "combination pharmacotherapy is the norm in patients with type 2 diabetes and comorbid conditions, and clinicians should routinely review the full medication list for overlapping adverse effect profiles rather than relying solely on pharmacokinetic interaction databases" [8].